EGFR and medullary thyroid gland carcinoma: Vandetanib, which inhibits VEGF receptor dependent tumor angiogenesis and epidermal growth factor receptor (EGFR-) and RET-mediated tumor cell proliferation, along with cabozantinib, is now FDA approved for treatment of medullary thyroid cancer [10].